Phase III INHIBIT Platform: Prevention Trial, Eloctate vs Emicizumab to Prevent Inhibitors; Eradication Trial: Eloctate Immune Tolerance (ITI) Plus Emicizumab vs vs Eloctate ITI Alone to Eradicate Inhibitors in Severe Hemophilia A
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Emicizumab (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics
- Acronyms INHIBIT
- 16 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 02 Jun 2019 Planned End Date changed from 1 Mar 2027 to 1 Jul 2027.
- 02 Jun 2019 Planned primary completion date changed from 1 Mar 2027 to 1 Jul 2027.